Aardvark Therapeutics to Present at the Stifel 2025 Virtual Cardiometabolic Forum

Core Insights - Aardvark Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule therapeutics for metabolic diseases, particularly targeting hunger suppression in conditions like Prader-Willi Syndrome [3] Company Overview - Aardvark is developing oral compound ARD-101, currently in Phase 3 clinical development for hyperphagia associated with Prader-Willi Syndrome, a rare disease characterized by insatiable hunger [3] - The company is also working on ARD-201, a fixed-dose combination of ARD-101 with a DPP-4 inhibitor, aimed at addressing limitations of existing GLP-1 therapies for obesity and related conditions [3] Upcoming Events - Aardvark will present at the Stifel 2025 Virtual Cardiometabolic Forum on September 30, 2025, at 9:00 a.m. Eastern time, with a live webcast available on their website [1][2]